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Abstract 24 
Objective: 25 
Antibiotic stewardship programs include development of practice guidelines incorporating 26 
local resistance patterns. The purpose of our study was to review the epidemiology of native 27 
septic arthritis to establish local guidelines for empirical antibiotic therapy. 28 
Methods:  29 
We conducted a ten-year retrospective study based on positive synovial fluid cultures and 30 
discharge diagnosis of septic arthritis in adult patients. Microbiology results and medical 31 
records were reviewed.  32 
Results: 33 
Between 1999 and 2008, we identified 233 episodes of septic arthritis. The predominant 34 
causative pathogens were methicillin-susceptible Staphylococcus aureus (MSSA) and 35 
streptococci (respectively 44.6% and 14.2% of cases). Only 11 cases (4.7%) of methicillin-36 
resistant Staphylococcus aureus (MRSA) arthritis were diagnosed, among which five (45.5%) 37 
occurred in known carriers. 38 
For large joint infections, amoxicillin/clavulanate or cefuroxime would have been appropriate 39 
in 84.5% of cases. MRSA and Mycobacterium tuberculosis would have been the most 40 
frequently uncovered pathogens. In contrast, amoxicillin/clavulanate would have covered only 41 
75.3% of small joint infections (82.6% if diabetics are excluded). MRSA and Pseudomonas 42 
aeruginosa would have been the main uncovered pathogens. Piperacillin/tazobactam would 43 
have been appropriate in 93.8% of cases (p<0.01 vs. amoxicillin/clavulanate). This 44 
statistically significant advantage is lost after exclusion of diabetics (p=0.19). 45 
Conclusions: 46 
Amoxicillin/clavulanate or cefuroxime would be adequate for empirical coverage of large 47 
joint septic arthritis. A broad-spectrum antibiotic would be significantly superior for small 48 
joints infections in diabetics. A systematic coverage of MRSA is not justified, but should be 49 
considered for known carriers. These recommendations are applicable to our local setting. 50 
They might also apply for hospitals sharing the same epidemiology. 51 
52 
Introduction 53 
Septic arthritis represents the most serious condition in the differential diagnosis of a hot 54 
swollen joint.
1-4
 The yearly incidence of septic arthritis varies from 2 to 10 per 100’000 55 
patients in the general population,
2-5
  but is up to ten times higher in high-risk patients such as 56 
those suffering from rheumatoid arthritis.
2,5,6
 Preexisting joint disease, diabetes, 57 
immunosuppressive treatments, prosthetic joints, intravenous drug use, older age and 58 
infection at a distant site are known risk factors.
1-3,5 
Attributed mortality ranges from 10 to 59 
15%,
7-9 
mostly because of concomitant bacteremia with virulent microorganisms.
2 
60 
Complications are frequent (around 30%), including loss of joint function subsequent to 61 
inflammation and release of lysosomal enzymes and bacterial toxins.
2,7-10
 Several risk factors 62 
and a delayed or inadequate treatment worsen the outcome of septic arthritis.
9,10
 Thus, prompt 63 
initiation of an adequate empiric treatment and drainage of purulent joint fluid (either 64 
surgically or by closed-needle aspiration) are of utmost importance to reduce morbidity and 65 
mortality.
1 
66 
 67 
Clinical presentation of septic arthritis lacks specificity, especially for patients with 68 
underlying joint disease. The diagnostic performance of signs and symptoms was recently 69 
reviewed, concluding that history and physical examination are not able to substantially 70 
change the pretest probability of septic arthritis in patients with an acutely painful, swollen 71 
joint.
11
 Sensitivity of fever in particular is only 57%. The arthrocentesis is most helpful in 72 
predicting septic arthritis. In particular, synovial white blood cells count and percentage of 73 
polymorphonuclear cells provide the best utility in identifying septic arthritis. 74 
Polymorphonuclear cell count of at least 90% suggests infection with a likelihood ratio of 3.4 75 
(95% confidence interval, 2.8-4.2). Gram stain sensitivity is variable and has been estimated 76 
from 29 to 52%.
11
 Although analysis of synovial fluid may be useful in increasing the pretest 77 
probability of septic arthritis, the initiation of an empiric antibiotic treatment is necessary 78 
while cultures are pending.  79 
 80 
Guidelines for accurate and rapid management of a suspected septic arthritis were recently 81 
published, with proposal of an empiric antibiotic therapy.
12
 These guidelines were mostly 82 
based on expert opinion, due to the paucity of well-designed studies answering the question of 83 
which empirical antibiotic therapy would perform better for septic arthritis.
13
 The authors 84 
suggested confronting these recommendations with the local resistance pattern to ensure an 85 
appropriate empiric therapy,
14
 in accordance with guidelines for antibiotic stewardship.
15
 86 
While Staphylococcus aureus and streptococci are commonly the most frequent pathogens in 87 
published series,
1-5,16,17
 other microorganisms show an obvious geographical variation (e.g. 88 
brucellosis, tuberculosis).
16,17
 In addition, although the distribution of microorganisms 89 
responsible for septic arthritis has been reported as stable over time,
18
 the incidence of multi-90 
drug resistant microorganisms is generally increasing, exhibiting a remarkable geographical 91 
variability.
19
 In particular, the frequency of methicillin-resistant Staphylococcus aureus 92 
(MRSA) and Pseudomonas aeruginosa infections are of concern for empiric therapy of septic 93 
arthritis.  94 
 95 
In an era of increasing bacterial resistance, the aim of our study was to review the 96 
epidemiology of septic arthritis and the antibiotic susceptibility profile of predominant 97 
causative pathogens in Western Switzerland in order to develop practice guidelines for 98 
empirical antibiotic therapy. 99 
 100 
Patients and methods 101 
We conducted a retrospective study on consecutive adult patients admitted with septic 102 
arthritis of a native joint in the University Hospital of Lausanne, an 850-bed tertiary care 103 
hospital in Western Switzerland, between January 1999 and December 2008. The design of 104 
this study was in accordance with the ethical standards of our hospital ethics committee. 105 
 106 
Case definition  107 
A case of adult native septic arthritis was defined as a > 16 year-old patient with a positive 108 
culture of synovial fluid and/or a discharge diagnosis of infectious arthropathy. Prosthetic 109 
joint arthritis was excluded.  110 
Cases were identified by reviewing positive cultures of synovial fluid samples in the 111 
microbiology database. Contaminations, bacteriological samples wrongly labeled as synovial 112 
fluid or alternative diagnosis (e.g. septic bursitis) were excluded. In addition, we reviewed 113 
hospital discharge diagnosis codes of infectious arthropathies (ICD-10, v.2007, codes M00.0 114 
to M01.1). Medical records of identified cases were assessed to confirm the diagnosis of 115 
septic arthritis. Data on comorbidities and specific risk factors (namely diabetes, documented 116 
pre-existing joint disease as osteoarthritis or inflammatory arthritis, intra-venous drug use, 117 
joint surgery or intra-articular injection in the previous 3 months) were collected. A former 118 
MRSA carriage was recorded from the infection control database. Hip, knee, shoulder, ankle, 119 
wrist, elbow, sternoclavicular and sacroiliac joints were classified as large joints. Joints of 120 
hands and feet were classified as small joints.  121 
 122 
Microbiology 123 
During the study period, a Gram stain was systematically performed on all synovial fluid 124 
samples. Samples were inoculated on standard blood agar, chocolate agar, McConkey agar 125 
and thioglycolate broth. The strains were identified at the species level using conventional 126 
phenotypic tests such as Vitek2 system (BioMérieux, Marcy l’Etoile, France) or the API 127 
system (BioMérieux). Antimicrobial susceptibility testing was performed using manuel disk 128 
diffusion methods according to CLSI (formerly NCCLS) guidelines or automated 129 
susceptibility testing using Vitek2 system (BioMérieux). When Mycobacterium tuberculosis 130 
arthritis was suspected on the basis of history and medical exam, fluorescent microscopy was 131 
applied on synovial fluid samples using acid fast stain (auramine). MGIT broth (Becton 132 
Dickinson, Sparks, Md.) and Lowenstein-Jensen medium were used for culture. 133 
Mycobacterial identification was performed using standard phenotypic and genotypic 134 
methods. The automated blood culture system was the Bactec 9240 (Becton Dickinson) with 135 
the Plus aerobic/F and Lytic anaerobic/F vials (Becton Dickinson).  136 
 137 
Antibiotic susceptibility 138 
Antibiotic susceptibility profile including amoxicillin, amoxicillin/clavulanate, cefuroxime, 139 
flucloxacillin and piperacillin/tazobactam of causative pathogens were reviewed for each 140 
case. These antibiotics were chosen according to the prescribing practice in our hospital and 141 
to recent guidelines.
1,12
 Our local antibiotic policy does not recommend the use of quinolones 142 
and carbapenems as empiric choices. 143 
During the study period, the proportion of MRSA in all clinical isolates of S. aureus increased 144 
from 4% in 1999 to 12% in 2008 in our hospital (mostly hospital-onset cases). Incidence of 145 
extended spectrum beta lactamases (ESBLs) producing gram-negative bacteria was low (2% 146 
of all E. coli isolates in 2009) and vancomycin-resistant enterococci remained extremely rare 147 
(<1%). 148 
 149 
Statistical analyses 150 
Categorical variables were compared using the chi-square or Fisher’s exact tests when 151 
appropriate; continuous variables were compared using the Mann-Whitney test. Analyses 152 
were conducted using the GraphPad Prism software (v. 5.03). 153 
 154 
Results 155 
Cases and classification 156 
During the ten-year study period, 233 cases of native septic arthritis were diagnosed in 231 157 
adult patients. Two intravenous drug users (IVDUs) presented recurrent infections. One 158 
hundred and seven episodes (45.9%) were identified through positive synovial fluid cultures, 159 
and 126 (54.1%) additional cases through the hospital discharge diagnosis codes. Among 160 
these 126 cases, 89 had wrongly-labeled positive synovial fluid cultures (samples mostly 161 
named as surgical swabs without precision), 14 had synovial samples that were processed in 162 
an external laboratory before admission, 12 had positive concomitant blood cultures, one had 163 
a negative synovial culture with a positive PCR, and ten remained of unknown bacterial 164 
etiology. 165 
 166 
Most septic arthritis involved large joints (147 episodes, 63.1%). Clinical characteristics of 167 
patients with large and small joint infections are presented in table 1. Only 4 (1.7%) 168 
polyarticular septic arthritis were observed, all involving large joints. 169 
 170 
Based on the review of medical records, hematogenous spread was the most likely 171 
pathogenesis for large joint infections (112 cases, 76.2%). Evolution from a contiguous focus 172 
(e.g. osteomyelitis, soft tissue infection) was predominant in case of small joint infections (81 173 
cases, 94.2%). Small joint septic arthritis concerned mostly foot joints in diabetic patients (33 174 
out of 36 episodes, 91.7%). 175 
 176 
Microbiology 177 
As expected, the predominant causative pathogens were Staphylococcus aureus (n = 115, 178 
49.4%) and streptococci (n = 33, 14.2%). Etiological agents differed between large and small 179 
joint infections (table 2). Small joint infections were more frequently polymicrobial (24.4% 180 
vs. 1.4%, p < 0.001). Only two cases of Neisseria gonorrhoeae infections were diagnosed, 181 
both involving large joints. In eleven patients, synovial fluid and/or other samples remained 182 
negative, mostly because of concomitant antibiotic therapy. In one of them, Streptococcus 183 
dysgalactiae was identified thanks to a 16S rDNA broad-spectrum PCR. The ten other cases 184 
remained of undetermined etiology (no PCR performed). Eleven out of 115 (9.6%) S. aureus 185 
isolates were methicillin-resistant. Five (45.5%) of the 11 MRSA cases occurred in known 186 
carriers.  187 
 188 
A percutaneous synovial fluid sample was available in 107 cases (72.8%) of large joint 189 
infections, and in 6 cases (7.0%) of small joint infections. Direct gram staining and 190 
microscopy was positive in only 33.6% of these 113 cases. In all cases of M. tuberculosis 191 
arthritis (n=7), auramine staining was negative. M. tuberculosis specific PCR was either 192 
negative or not performed.  193 
 194 
Thirty-five episodes of septic arthritis (15.0%) occurred in 33 IVDUs. Among this subgroup 195 
of patients, methicillin-susceptible Staphylococcus aureus (MSSA) was by far the most 196 
commonly involved pathogen (25 cases, 71.4%). No MRSA and only one case of P. 197 
aeruginosa arthritis were observed.  198 
 199 
Seventy episodes of septic arthritis (30.0% of all, 23.1% of large and 42.0% of small joint 200 
infections) occurred in diabetic patients. MSSA was also the main causative microorganism 201 
(28 cases, 40.0%). Gram-negative bacteria (namely 2 Escherichia coli, 1 Enterobacter 202 
cloacae, 3 Morganella morganii, 3 Pseudomonas aeruginosa, 1 Pantoea spp, and 2 Proteus 203 
spp) were responsible for 12 cases (17.1%). Eleven of these cases were polymicrobial 204 
(15.7%). 205 
 206 
Antibiotic susceptibility 207 
Overall antibiotic susceptibility profiles of causative pathogens to amoxicillin, 208 
amoxicillin/clavulanate, cefuroxime, flucloxacillin and piperacillin/tazobactam were 209 
systematically reviewed and are summarized in table 3. No Gram-negative bacteria produced 210 
ESBL.  211 
 212 
Performances of various empirical antibiotic therapies 213 
For large joint infections, amoxicillin/clavulanate or cefuroxime would have been appropriate 214 
in 84.5% of cases (table 4). MRSA (8 cases) and Mycobacterium tuberculosis (7 cases) would 215 
have been the most frequently uncovered pathogens. Addition of vancomycin in previously 216 
known MRSA carriers (4 patients) would have only slightly increased the global 217 
appropriateness to 87.3%. Exclusion of M. tuberculosis cases would increase the 218 
appropriateness of empiric amoxicillin/clavulanate or cefuroxime to 88.8%. An anti-219 
pseudomonal penicillin (piperacillin/tazobactam) would not have performed significantly 220 
better (88.0%, p=0.4 vs. amoxicillin/clavulanate or cefuroxime). 221 
 222 
In contrast, empiric amoxicillin/clavulanate would have been appropriate in only 75.3% of all 223 
small joint infections. This rate would increase to 82.6% if diabetic patients are excluded. 224 
MRSA (3 cases, of which one occurred in a previously known carrier) and P. aeruginosa (9 225 
cases, of which 7 are monomicrobial) would have been the main uncovered pathogens. 226 
Piperacillin/tazobactam would have been appropriate in 93.8% of cases of small joint 227 
infections (p < 0.01 vs. amoxicillin/clavulanate). This statistically significant advantage is lost 228 
after exclusion of diabetic patients (p=0.19 vs. amoxicillin/clavulanate). When considering 229 
only diabetic patients with small joint infections, piperacillin/tazobactam was appropriate in 230 
94.3% of cases vs. 65.7% for amoxicillin/clavulanate (p=0.01). 231 
 232 
Discussion 233 
In order to establish guidelines for empirical antibiotic therapy, we reviewed the 234 
epidemiology of septic arthritis over the last ten years in Western Switzerland and assessed 235 
the overall antibiotic susceptibility profile of causative pathogens. Two hundred thirty-three 236 
consecutive cases were analyzed. Due to the high proportion of wrongly-labeled synovial 237 
fluid specimens, the additional review of hospital discharge diagnosis codes identified 54% of 238 
all cases and should therefore be included in a review process to be exhaustive. Most of the 239 
previous large series were published in the eighties and nineties, 
4,5,7,9,10,16
 and only scarce 240 
recent data are available.
8,17,18
 Globally, the main pathogens are concordant with previous 241 
studies,
1-5,8-10
 staphylococci and streptococci being the most frequently recovered 242 
microorganisms. Incidence and species of gram-negative pathogens differed between large 243 
and small joint septic arthritis and according to underlying comorbidities such as diabetes. 244 
Gonococcal and mycobacterial arthritis were rare in our setting. Mycobacterial infections 245 
were included in our analysis as clinical presentation of this pathogen may be 246 
indistinguishable from other causes of septic arthritis,
20
. Only ten septic arthritis cases (4.3%) 247 
remained of undetermined etiology.  248 
 249 
Based on our local epidemiology, amoxicillin/clavulanate or cefuroxime are adequate for 250 
empirical treatment of large joint septic arthritis and can be recommended in local guidelines. 251 
An anti-pseudomonal antibiotic was not superior in this setting. In contrast, 252 
piperacillin/tazobactam performs significantly better in the subgroup of diabetic patients with 253 
small joint infections, mostly due to the higher incidence of P. aeruginosa. We could not 254 
reliably consider the possible impact of a previous antibiotic therapy or recent hospitalization 255 
due to the frequently missing information in medical records. In diabetic patients with small 256 
joint infections, most cases arose from a contiguous focus (100%, soft tissue and/or 257 
osteomyelitis) and concerned foot joints (91.7%). This argues for chronic infections and 258 
possible previous outpatient antibiotic treatment. The use of broad-spectrum antibiotic in this 259 
specific clinical setting is in agreement with recommendation of empirical therapy for severe 260 
diabetic foot infections.
21-23
Further data are needed to determine if a narrower spectrum 261 
antibiotic therapy may be adequate for diabetic patients with small joint acute infections 262 
without previous antibiotic therapy.  263 
 264 
Septic arthritis due to MRSA remained also rare during the study period (11 cases, 4.7% of all 265 
episodes). Although resistant strains emerged soon after the introduction of methicillin in 266 
1961 and progressively became endemic worldwide,
24
 many series published between 1976 267 
and 2007 do not mention the quantitative importance of MRSA in the setting of S. aureus 268 
arthritis.
1,5,6,8-10,16,17
 Only some studies performed in high MRSA incidence areas report a 269 
proportion of septic arthritis due to MRSA ranging from 2 to 25% of all cases.
18,25-27
 As 270 
clinical presentation, patients’ demographics and comorbidities do not reliably permit to 271 
distinguish MRSA from MSSA septic arthritis,
27
 guidelines for empirical antibiotic therapy 272 
have to consider the local epidemiology. Almost half of our cases were known carriers before 273 
the septic arthritis. This is in agreement with studies demonstrating the significant risk of 274 
subsequent infections in prevalent MRSA carriers.
28,29
 If the global frequency of MRSA 275 
septic arthritis does not justify systematic empiric coverage of this pathogen in our setting, an 276 
adapted empirical treatment should be considered for known carriers. 277 
 278 
Evaluation of septic arthritis in IVDUs showed that MSSA remained the leading etiological 279 
agent. P. aeruginosa septic arthritis has been reported mostly in small studies from the 280 
eighties including heroin addicts.
30,31
 At that time, usage of pentazocine, a synthetic opiate 281 
dissolved and injected without heating, was frequently associated with bacteremia due to 282 
environmental bacteria like P. aeruginosa. The parenteral usage of pentazocine ended in 1983 283 
when the manufacturer added naloxone to stop its narcotic use.
32
 A serie of 180 284 
sternoclavicular infections, a frequent localization in IVDUs, reported a drop of P. aeruginosa 285 
arthritis rate from 82% before 1981 to 14% after 1981, and its concomitant substitution by S. 286 
aureus infections.
33
 Our results are in agreement with this general trend and allow us not to 287 
consider empiric coverage of P. aeruginosa in IVDUs. Although intravenous drug use has 288 
been locally recognized as a risk factor for infection with community-associated MRSA,
34
 our 289 
data do not provide any evidence for dissemination of this pathogen in our population of 290 
IVDUs. 291 
 292 
By definition, our recommendations are only applicable to our local setting, although they 293 
might also apply for hospitals sharing the same epidemiology of resistant pathogens. Due to 294 
the retrospective design of our study, a precise description of the clinical initial presentation 295 
and a meticulous review of some risk factors were not possible. In particular, we could not 296 
integrate the detailed immunosuppressive medication or anamnestic elements indicating a 297 
previous urinary bacteremia or risk factors for sexually transmitted diseases. Usage of broad-298 
spectrum and pathogen specific PCR for negative synovial fluid cultures was not 299 
systematically available before 2002 (confirmer la date). However, this should not have 300 
biased our analysis in minimizing resistant pathogens.  301 
 302 
In summary, this ten-year review of the epidemiology of septic arthritis in Western 303 
Switzerland allowed us to extrapolate an appropriate empirical therapy for this local setting. 304 
These recommendations are only applicable to our local setting, although they might also 305 
apply for hospitals sharing the same epidemiology of resistant pathogens. Due to the changing 306 
incidence of resistant pathogens over time, the adequacy of this proposal should be validated 307 
on a regular basis.  308 
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389 
Table 1: Comparison of clinical characteristics between patients with large and small 390 
joint arthritis 391 
 392 
 Large joints 
N = 147 
Small joints 
N = 86 
P value 
Male gender 91 (61.9%) 57 (66.3%) 0.57 
Mean age (years) 57.6 63.3 0.07 
Co-morbidities    
Diabetes 34 (23.1%) 36 (41.8%) < 0.01 
IVDU
1 
28 (19.0%) 7 (8.1%) 0.04 
Preexisting joint disease 62 (42.2%) 56 (65.0%) < 0.01 
Previous joint surgery/puncture 11 (7.5%) 1 (1.2%) 0.06 
Localization    
Knee 57 (38.8%) -  
Hip 26 (17.7%) -  
Shoulder 24 (16.3%) -  
Ankle 13 (8.8%) -  
Wrist 13 (8.8%) -  
Sternoclavicular 6 (4.1%) -  
Elbow 3 (2.0%) -  
Sacroiliac 1 (0.7%) -  
Hand    
Metacarpo-phalangeal - 12 (14.0%)  
Distal interphalangeal - 9 (10.5%)  
Proximal interphalangeal - 5 (5.8%)  
Foot    
Metatarso-phalangeal - 28 (32.6%)  
Proximal interphalangeal - 27 (31.4%)  
Distal interphalangeal - 5 (5.8%)  
Polyarticular 4 (2.7%) 0  
 393 
1
IVDU = intravenous drug user 394 
395 
Table 2: Causative pathogens 396 
 397 
Pathogens Large joints 
N = 147 
Small joints 
N = 86 
Total  
N = 233 
Staphylococcus aureus    
MSSA 78 (53.1%) 26 (30.2%) 104 (44.6%) 
MRSA 8 (5.4%) 3 (3.5%) 11 (4.7%) 
Streptococcus spp 20 (13.6%) 13 (15.1%) 33 (14.2%) 
Coagulase-negative staphylococci 3 (2.0%) 3 (3.5%) 6 (2.6%) 
Other Gram-positive bacteria¹ 5 (3.4%) 2 (2.3%) 7 (3.0%) 
Pseudomonas aeruginosa² 4 (2.7%) 7 (8.1%) 11 (4.7%) 
Escherichia coli² 6 (4.1%) 0 6 (2.6%) 
Neisseria gonorrhoeae 2 (1.4%) 0 2 (0.9%) 
Other Gram-negative bacteria²
,3
 7 (4.8%) 6 (7.0%) 13 (5.6%) 
Mycobacterium tuberculosis 7 (4.8%) 0 7 (3.0%) 
Polymicrobial 2 (1.4%) 21 (24.4%) 23 (9.9%) 
Unknown 5 (3.4%) 5 (5.8%) 10 (4.3%) 
 398 
¹ Large joint infections: 2 Propionibacterium acnes, 3 Streptococcus pneumonia (penicillin-399 
susceptible). Small joint infections: 1 Enterococcus spp (vancomycin-susceptible), 1 400 
Corynebacterium spp 401 
² No extended spectrum beta lactamases (ESBLs) producing gram-negative bacteria 402 
3
 Large joint infections: 2 Neisseria spp, 1 Proteus vulgaris, 1 Pantoea spp, 1 Haemophilus 403 
influenzae, 1 Enterobacter cloacae, 1 Brucella spp. Small joint infections: 3 Morganella 404 
morganii, 1 Enterobacter cloacae, 1 Fusobacterium nucleatum, 1 Proteus mirabilis. 405 
406 
Table 3: Overall antibiotic susceptibility profiles of causative pathogens 407 
 408 
Antibiotic Large joints 
N = 142
1 
Small joints 
N = 81
1 
Total  
N = 223
1 
Amoxicillin 45 (31.7%) 27 (33.3%) 72 (32.3%) 
Amoxicillin/clavulanic acid 120 (84.5%) 62 (76.5%) 182 (81.6%) 
Cefuroxime 120 (84.5%) 59 (72.8%) 179 (80.3%) 
Flucloxacillin 107 (75.4%) 54 (66.7%) 161 (72.2%) 
Piperacillin/tazobactam 125 (88.0%) 76 (93.8%) 201 (90.1%) 
 409 
1
Ten septic arthritis cases remained of unknown etiology and were excluded from this 410 
analysis (5 large joint and 5 small joint infections).  411 
 412 
413 
Table 4: Performance of empirical antibiotic therapy on coverage of causative pathogens 414 
 415 
 Amoxicillin/clavulanic 
acid  
Piperacillin/tazobactam 
 
P value 
 
Large joints 120/142 (84.5%) 125/142 (88.0%) 0.4 
Small joints 61/81 (75.3%) 76/81 (93.8%) < 0.01 
 Diabetics 23/35 (65.7%) 33/35 (94.3%) < 0.01 
 Non-diabetics 38/46 (82.6%) 43/46 (93.5%) 0.19 
All 182/223 (81.6%) 201/223 (90.1%) 0.01 
 416 
